Hello, and welcome to the Mettler-Toledo third quarter 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session, and if you would like to ask a question, please press star one. I would now like to turn the conference over to Adam Uhlman, Head of Investor Relations. You may begin. Hey, thanks, Sarah, and good morning, everyone. Thanks for joining us. On the call with me today is Patrick Kaltenbach, our Chief Executive Officer, and Shawn Vadala, our Chief Financial Officer. Let me cover some administrative matters. This call is being webcast and is available for replay on our website at mt.com. A copy of the press release and the presentation that we will refer to on today's call is available on our website. This call will include forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934. These statements involve risks, uncertainties, and other factors that may cause our actual results, financial condition, performance, and achievements to be materially different from those expressed or implied by any forward-looking statement. For a discussion of these risks and uncertainties, please see our recent annual report on Form 10-K and quarterly and current reports filed with the SEC. The company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements except as required by law. On today's call, we may use non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable measures is provided in the 8-K and is available on our website. Let me now turn the call over to Patrick. Thanks, Adam, and good morning, everyone. We appreciate you joining our call today. Last night, we reported our third quarter financial results, the details of which are outlined for you on page three of our presentation. We experienced good growth during the third quarter in our Laboratory business and had particularly strong growth in service. While China grew modestly this quarter, market conditions remained challenging, particularly in the Industrial sector. We are very pleased with our team's strong execution of our growth and margin expansion initiatives, which supported good earnings growth in the quarter. We continue to execute very well and will benefit from the prior year's shipping delays in the fourth quarter. However, global market conditions remain soft. We have introduced many exciting innovations as well as next generations of our Spinnaker sales and marketing and SternD rive productivity programs over the past year. We also continue to leverage our business diversity and ability to provide value throughout our customers' value chain to identify and capture growth opportunities and believe we are very well positioned to gain market share and deliver good earnings growth in the future. Let me now turn the call over to Shawn to cover the financial results and our guidance, and then I will come back with some additional commentary on the business and our outlook. Shawn? Thanks, Patrick, and good morning, everyone. Sales in the quarter were $954.5 million, which represented an increase in local currency and in U.S. dollars of 1%. On slide number four, we show sales growth by region. Local currency sales grew 1% in Europe, declined 1% in the Americas, and grew 4% in Asia and the rest of the world. Local currency sales increased 1% in China in the quarter. On slide number five, we show sales growth by region for the first nine months of the year. Local currency sales were flat for the first nine months, with 4% growth in Europe, 1% growth in the Americas, and a 6% decline in Asia and the rest of the world. Local currency sales decreased 15% in China on a year-to-date basis. As a reminder, our first quarter sales benefited by 6% from recovering delayed product shipments, which is a 2% benefit to our year-to-date results. Excluding this, our local currency sales declined 2% on a year-to-date basis. On slide number six, we summarize local currency sales growth by product area. For the quarter, Laboratory sales increased 5% and Industrial was flat, with Core Industrial down 1% and Product Inspection up 1%. Food Retail declined 20% in the quarter against significant project activity last year. The next slide shows local currency sales growth by product area for the first nine months. Laboratory sales increased 2% and Industrial decreased 2%, with Core Industrial down 4% and Product Inspection up 1%. Food Retail decreased 14% on a year-to-date basis. Let me now move to the rest of the P&L, which is summarized on slide number eight. Gross margin was 60%, an increase of 60 basis points as positive price realization and benefits from our SternD rive program were partially offset by lower volume. R&D amounted to $47.1 million in the quarter, which is a 1% increase in local currency over the prior period. SG&A amounted to $228.8 million, a 5% increase in local currency over the prior year and includes higher variable compensation. Adjusted operating profit amounted to $296.6 million in the quarter, unchanged from the prior year. Adjusted operating margin was 31.1%, which represents a decrease of 30 basis points over the prior year. A couple of final comments on the P&L. Amortization amounted to $18.2 million in the quarter. Interest expense was $18.6 million, and other income amounted to $1.9 million. Our effective tax rate was 19% in the quarter. This rate is before discrete items and is adjusted for the timing of stock option exercises. Fully diluted shares amounted to 21.2 million, which is approximately a 3% decline from the prior year. Adjusted EPS for the quarter was $10.21, a 4% increase over the prior year. On a reported basis in the quarter, EPS was $9.96 as compared to $9.21 in the prior year. Reported EPS in the quarter included $0.23 of purchased intangible amortization, $0.10 of restructuring costs, and a $0.08 tax benefit from the timing of option exercises. The next slide illustrates our year-to-date results. Local currency sales were flat for the nine-month period. Adjusted operating income decreased 3% or declined 1%, excluding unfavorable foreign currency. And our adjusted operating margin contracted 50 basis points. Adjusted EPS was flat on a year-to-date basis and grew 2%, excluding unfavorable currency. That covers the P&L, and let me now comment on adjusted free cash flow, which amounted to $671 million for the first nine months, a 7% increase on a per-share basis from the prior year levels due to favorable working capital. DSO was 36 days, while ITO was four times. Let me now turn to our guidance for the remainder of this year and our initial thoughts on next year. As you review our guidance, please keep in mind the following factors. Market conditions remain soft, especially in China. While we are not seeing a negative change in market conditions, we are also not seeing a significant improvement. Secondly, while there is uncertainty in our core markets, the global economy, and geopolitics, we expect market conditions to gradually improve throughout 2025. We also expect to continue to benefit from customer trends in automation, digitalization, and on-and-near shoring. Third, we assume foreign currency at current rates. And finally, please keep in mind that our third-party logistics provider delays negatively impacted our Q4 results last year by $58 million, nearly all of which was recovered in our first quarter sales results this year. This will benefit our Q4 2024 sales growth by approximately 6% and will reduce our sales growth in 2025 by 1.5%. This also negatively impacts our margin expansion in 2025. Now, turning to our guidance for the fourth quarter of 2024, we expect local currency sales to grow by approximately 8%. This includes an expected benefit of approximately 6% from the prior year shipping delays. We expect adjusted EPS to be in the range of $11.63-$11.78. Currency for the quarter at recent spot rates would be neutral to fourth quarter sales and adjusted EPS. For the full year 2024, our local currency sales growth forecast is unchanged at approximately 2% or down 1%, excluding the previously mentioned shipping delays. We expect full-year adjusted EPS to be in the range of $40.35-$40.50, up $0.15 on the low end of our prior guidance range. Free cash flow and share repurchases for 2024 are expected to be approximately $850 million. We have also provided our initial guidance for 2025. And based on our assessment of market conditions today, we would expect local currency sales to increase approximately 3%, which includes the previously mentioned headwind to full-year sales growth of 1.5% from the shipping delays that benefited 2024. Adjusted EPS is forecast to be in the range of $41.85-$42.50, which represents a growth rate of 4%-5%. At recent spot rates, foreign exchange is estimated to be a slight headwind to adjusted EPS growth. Lastly, I would like to share a few other details on our 2025 guidance to help you as you update your models. We expect total amortization, including purchased intangible amortization, to be approximately $75 million. Purchased intangible amortization is excluded from adjusted EPS and is estimated at $24.8 million on a pre-tax basis or $0.92 per share. Interest expense is forecast at $82 million for the year, and other income is estimated at approximately $2 million. We expect our tax rate before discrete items will remain at 19% in 2025. Free cash flow is forecast at approximately $860 million in 2025, and share repurchases are expected to be approximately $875 million. That's it from my side, and I'll now turn it back to Patrick. Thanks, Shawn. Let me start with some comments on our operating businesses, starting with LAT, which grew approximately 5% compared to last year. We had good growth across most of the portfolio and regions and continue to benefit from our robust offering and recent innovations, as well as our initiatives to accelerate growth in service and consumables. Pharma customer activity has been mixed but improving at a low pace. Our Process Analytics business returned to solid growth this quarter as our bioproduction customers have finished destocking excess inventories. To expand our already broad portfolio of instruments we offer to our Laboratory customers, we recently launched a new stain-free automated cell counter and a new microplate reader to help our customers in R&D and QA/QC labs. These new products add further to the long list of innovations we have brought to the market in recent years and expand our technology leadership. Shifting now to our Industrial business, sales for the quarter were flat and slightly lower than expected, primarily due to market headwinds in China. Product Inspection sales growth of 1% benefited from our growth initiatives targeting the mid-market, but the food manufacturing industry remains challenged overall. Our Core Industrial sales declined 1%, reflecting sluggish market conditions across most industries. Our team remains active in leveraging Spinnaker to identify and capture the most attractive market opportunities in Core Industrial, which has reduced our sensitivity to the economy, although we are not immune. Additionally, we have further enhanced our portfolio and have expanded our line of weighing terminals that feature integrated software solutions, leveraging advanced algorithms. These new terminals provide process automation control for many different filling and dosing workflows, seamlessly integrating into customer systems. Lastly, shifting to our Food Retail business, as I mentioned earlier, our Food Retail sales declined against a very significant project-related growth in the prior year. Now, let me make some additional comments by geography. Starting in the Americas, our sales declined 1% in the quarter. We had good growth across our LAT portfolio with pharma customers, while Food Retail declined against very significant growth in the prior year. Core Industrial sales declined slightly as demand for our automation-related solutions was offset by lower demand in other areas. Sales in Europe grew 1% in the quarter and included growth both from Laboratory and Core Industrial, benefiting from modest growth from pharma customers, while food manufacturing remained soft. Our teams in Europe continue to execute well despite challenging economic conditions across the region, and finally, our Asia/Rest of the World results this quarter were in line with our expectations. Our China operations returned to sales growth in the quarter due to easier comparisons and strong execution of our sales team, but underlying demand remained soft due to weak economic growth and excess capacity in certain industries. Our teams across Asia continue to execute very well on driving sales and market share growth. Targeting growth in emerging markets such as Southeast Asia and India remains an important element of our long-term growth strategy. In summary, market conditions overall have remained challenged, but our team is executing very well. We have continued to fund important growth investments in areas like innovation and field sales and service, while we have reinforced our unique go-to-market strategies with the launch of the next wave of Spinnaker. In 2025, we will make additional targeted investment in these areas to further extend our market leadership and strengthen our competitive advantages. An important element of our growth algorithm is gaining market share in our highly fragmented markets and pursuing growth opportunities in faster-growing market segments. Spinnaker helps us identify these new growth opportunities and guides our sales force to ensure we maximize our potential. We continue to see significant market trends and opportunities related to the localization of strategically important technologies, investments to develop new energy solutions for the future, and efforts to increase resilience in supply chains around the world. At the same time, customers continue to seek productivity and insights through automation and digitalization. Spinnaker encompasses our lead generation programs with existing customers, and it houses our Top K program to identify growth opportunities with potential new customers. Top K uses proprietary data analytics on our internal big data warehouse and external data sources to identify and pursue opportunities. Our teams are expanding our capabilities in this area to automate more of the qualification processes and accelerating the rate that we can generate tailored and actionable investment alerts for our field sales force. This program has been very important in driving lead growth with new customers this year, and our team remains focused on expanding our data sets and adding sophisticated analytics and automation to enhance this program in 2025. Another important driver for our long-term growth is to accelerate the growth of our service business. As a reminder, service represents approximately 25% of our sales and has grown 7% on a year-to-date basis in local currencies, which includes very strong growth of 9% in the third quarter. Service will continue to be an important growth driver in the future. Service is a key part of our solutions offering and is a very important competitive advantage as we support our customers' ability to maintain uptime, improve productivity, and comply with regulatory requirements. We believe we have the largest service network among our direct competitors with over 3,000 technicians delivering a very professional and consistent service experience to customers throughout the world. Our customer satisfaction ratings for our service business and our net promoter scores are excellent and are at record-high levels. We aim to grow our service business faster than the company average over the medium term and are making dedicated investments in field technicians, in telesales, and data analytics resources to support our growth aspirations. Additionally, we continue to benefit from our actions to improve the productivity of our service organization and increase its capacity to serve customers, including leveraging new software capabilities to estimate service durations, semi-automated scheduling of service visits, and utilizing expanded call triage capabilities to resolve service requests remotely and reduce trips to our customer locations. We are also expanding the use of sophisticated data analytics and automation technologies to increase the effectiveness of our dedicated service sales team. Our largest opportunity is servicing a greater proportion of our installed base, which approximates $3 billion of potential service revenue. Today, we have penetrated about one-third of this opportunity and, given the vast amount of data we possess about it, like when an instrument was sold, who is using it, in what application it's being used, we can create targeted sales campaigns to service them specifically tailored to their needs based on our data. This will help further expand our coverage. Service contracts help ensure that the measurements from our precision instruments are reliable and also help prevent costly downtime. We have maintained our focus on selling more service packages at the point of new product sale. Over the years, we have made important enhancements and differentiation to service levels of prepaid contracts to meet the varying needs of our customers. We have also enhanced our portfolio of services over the years with solutions like our RapidCal tank scale calibration service. Regular calibration of tank scales is required across industries such as pharma and chemical to ensure measurements are accurate and reliable. Our RapidCal service can calibrate these scales three times faster than traditional methods and also does not require a tank to be emptied, cleaned, and filled with expensive ultra-pure water that would need to be discharged afterwards. So it is not only faster, but also much more efficient and environmentally friendly. We have also enhanced our offering of certified calibration certificates to ensure compliance with regulations and avoid cost of inaccurate measurements. Our calibration services are highly differentiated from the competition and include our comprehensive and audit-proof electronic documentation that adheres to the highest standards or to the highest industry standards. So that is a brief overview of the efforts we have underway to accelerate our growth by reinforcing our unique go-to-market approaches with Spinnaker, identifying and capturing growth opportunities with new customers and growth industries, and accelerating the growth rate of our service business. We expect our focused execution on these initiatives will continue to deliver very tangible benefits over the next year and beyond. Now, this concludes our prepared remarks. Operator, I'd now like to open the line to questions. Thank you. If you would like to ask a question, please press star one on your telephone keypad. If you would like to withdraw your question, simply press star one again. Please ensure that your phone is not on mute when called upon. Thank you. Your first question comes from the line of Vijay Kumar with Evercore ISI. Your line is open. Hi, guys. Good morning, and thanks for taking my question. Patrick, maybe my first one for you on the fiscal 2025 assumptions here. I think the 150 basis points had been the underlying mid-singles. It's in line with peers. What are you assuming for labs versus industrials? And I think your comments on services were helpful. Is services still expected to grow in the mid-singles plus high singles in fiscal 2025? Yeah. So let me start with the last part of the question, and I'll let Shawn walk you through the details on the growth expectations of the different segments. So services, yes, we expect to continue to grow above company average. So we expect it to continue to meet high single-digit next year. As I said in my prepared remarks here, we are investing quite heavily in our service business, not only in expanding our service portfolio, but also strengthening our telesales team, leveraging more data to reach to the installed base. And tapping into that installed base that we don't cover yet today is a significant growth opportunity for us in the future. So Shawn, will you walk Vijay through the details of the segment? Yeah. Hi, Vijay. Hey, maybe I'll just walk you through the different assumptions for 2025. And I'll do it on a reported basis, but I'll also do it adjusting for the headwinds on the shipping delays, just so that's clear. So our lab business, we're assuming, will grow low- to mid-single-digit on a reported basis, but will grow mid- to high-single-digit, excluding the headwind of the shipping delays. Our Core Industrial business and our Product Inspection businesses are both estimated to grow low-single-digit on both the reported and an adjusted basis. And that would be the same for, obviously, our total industrial business. And then our retail business is expected to be flat next year or up low-single-digit, adjusted for the shipping delays. And then I'll give you the regions too, since we're doing it. Americas, on a reported basis, is expected to grow low to mid-single digit. And on an adjusted basis for the shipping delays, it would grow mid-single digit. Our European business is expected to grow low single digit on a reported basis. And adjusted for the shipping delays, it would grow mid-single digit. And then China is expected to grow low single digit on both the reported and adjusted basis. That's helpful, Shawn. And maybe one on that margins here, EPS guidance. I know you guys start typically conservative. What are you assuming for operating margin expansion for fiscal 2025 and our service margins above corporate? Yeah, so our operating margin for next year is expected to be flattish to this year, maybe up slightly. Our service business, yeah, does have a margin above the corporate average, but hey, maybe I use this as an opportunity to talk about maybe some of the optics about the shipping delays on earnings, because I can imagine that's a challenge to try to understand the guidance, so we talked about the first optic, which is on sales. And then from a sales perspective, it's a 1.5% headwind. I think that's pretty well understood, so our organic sales growth for 2025 is expected to be 4.5% adjusted for the timing of the shipping delays. But there's also a very meaningful impact on our EPS growth as well and our margin expansion, especially since most of our products that were affected are in our lab business, which are at above average margins. And you can kind of see this if you think about the operating profit margin compression in Q4 of last year and the operating margin expansion in our Q4 guidance of this year. If you look at our Q4 guidance of this year, it implies an operating margin expansion over last year of about 320 basis points or so. And directionally, we're going to see something, we're not going to give out details at this time for Q1, but directionally, you're going to see something similar in terms of margin compression in Q1 of 2025. And then after that, we should get back to more normal cadence. If you think about it, it kind of makes sense if you think about our overall gross margin percentage and the related incrementals associated with timing shifts, because they're going to be a little bit higher because of the nature of our fixed cost structure. We also wanted to communicate if we didn't have this effect of these shipping delays, our EPS growth guidance would be more in line with our typical relationship between sales growth and EPS growth. We'd estimate it'd probably be about 4% higher to our EPS guidance. We also have a couple of other additional items. The first is variable compensation in 2024 is not back to target levels, so we'll have a little bit of a headwind for that in 2025. Currencies are slightly unfavorable to EPS at the moment too, and we mentioned that in the script. But when we step back from all that, the other message we wanted to make sure we could communicate today too is that we still have a lot of very exciting opportunities to invest in the business, and we're not going to slow down these investments just because of the optics of the shipping delay to our sales growth. And I think that's important because I think we have a lot of good things in the pipeline that we're investing in. And also just to remain, the other thing we wanted to communicate is that we do remain very confident about our ability to grow earnings and expand margins going forward in accordance with our medium to long-term guidance. Understood. Thanks, guys. The next question comes from Matt Sykes with Goldman Sachs. Your line is open. Hi, good morning. Thanks for taking my questions. Patrick, maybe just first on services, you guys gave a lot of great color in your prepared comments. One thing I'm just curious about, and understanding that margins are already above corporate average, just curious about the level of operating leverage you can extract from services, understanding the 3,000 technicians you already have. It sounds like you're willing to make more investments in that. I'm just wondering on the technology and automation side, how much of that can offset maybe increased hiring to create operating leverage in the services business margin? Yeah. Thanks, Matt. That's a great question. And of course, we continuously also can improve the effectiveness of our service team. I mentioned a little bit in the call that we're using special software capabilities, including deep learning algorithms, to understand how we can most effectively schedule services and also with that drive up efficiency of our technicians in the field. And we make continuous improvements along this. On our platform, we just recently also launched a new service template that takes care of that to make sure that we most effectively use our service technicians. We are, of course, also changing more and more of our future product portfolio with more remote service capabilities and with that driving more efficiency of the service team as well. But that said, I mean, we still will expand probably headcount in service as well, not only on the technician side, but also making sure that we have enough support to drive marketing campaigns and lead generation for services out there. I talked a little bit about this untapped opportunity of instruments that we have in the field that we don't service today. We have information, again, as I said, when they have been bought, where they are, what application they are used for. And we are now getting back to these customers, reaching out to them and offering new and broader service portfolio. And to service these instruments and these solutions will require also more technicians in the future. I think it's a great growth opportunity. I think it's something also that leads to strong customer satisfaction. Our net promoter scores and services are outstanding. Customers love our service, not only because of the proficiency, but also helping them with compliance, etc. So again, it's a strong growth driver for us moving forward and also helping us on the margin expansion. But it will require also investments in headcounts. Besides all the efforts we do and we continue to do this in driving efficiency with smarter software solutions, again, deep learning algorithms, and we have data scientists in the group as well using in the future also more knowledge management tools to understand really how we can more efficiently drive the information to service engineers that we can reduce dual visits to customers, etc., making sure that they have all the right information when they get to the customer, etc., to make sure we can increase and maximize first-time fixes, etc. So there's a lot of opportunities. That's why we are continuing to invest in this, and we'll see in the next years to come also nice growth from this business. Great. Thanks for that color, Patrick. And then just on China, understanding your guidance for next year for low single digit growth, just curious, how much stimulus impact are you kind of assuming in that growth rate? And then just more longer term, how have you changed your assumptions on longer-term China growth as it faces your business? Just curious to see if that's been adjusted. I know there's a lot of different potential headwinds that could come in, but just curious about how your framing of that growth has changed. Yeah. Excellent. Yes. Look for next year in a question regarding the stimulus. We have not factored anything regarding stimulus in our forecast of low single-digit for next year. As you probably also have heard from some of our competitors, it's pretty unclear yet when the stimulus will really gain traction, so we take a more cautious approach here when we forecast the growth for next year. With the last stimulus that came out, our team is still actively working with our customers, making sure that they can bundle solutions in the right way so they basically can apply for the stimulus that is out there, but I don't think it will have a meaningful impact this year, and we also have not factored anything yet in for next year, and that basically brings us into the low single-digit growth model for next year. Long-, mid-, and long-term, we think there's still very good potential for us in China. We have not changed our long-term outlook of high single-digit growth in China. Yes, it will have to come back to growth in many areas. But I think the fundamentals in China, investing into healthcare, into safer, cleaner environment, and safer food, investing in important technologies like semiconductors, etc., they're all areas where we serve our customers with dedicated solutions. We have a great team in China that works very closely in China with our customers to develop solutions for the Chinese market. And it also makes us compete very effectively against local players. So I think we have a great opportunity to continue also there to drive market share and participate in the underlying growth, but on top of that, gain market share. That's why we have not changed the long-term model for China. Thank you very much. The next question comes from Dan Arias with Stifel. Your line is open. Morning, guys. Thanks for the questions here. Shawn or Patrick, maybe just another one on the outlook for 2025. Obviously, a lot of moving parts out there. Where, as you sit today, do you see the biggest sources of variability when it comes to what could have you better or worse than the initial outlook? Obviously, China is a big one, so I get that. But if there's more to add there, then by all means. But beyond China, I'm just kind of interested in where you see the error bars as being the widest when it comes to just the businesses or the key regions that you have. Yeah. Hey, Dan, this is Shawn. I'll take that. I mean, I think you said it. I mean, China, we've always said in the past, things can move relatively fast and quickly in either direction. And I'm sure it will continue to have zigs and zags along the way. So we certainly see upside to the guidance in China. But who knows how things develop here over the next year? Other swing factors, I mean, of course, our end markets are a big part of that. When do companies really get back to moving forward with a lot of projects that have been on the sidelines recently? I think you guys all know what our core secular exposures are. But you kind of quickly just get into things outside of our control, whether it's market conditions, macro, geopolitics, those types of things. But in terms of what we can control, we feel very good about that. The teams just continue to execute really well. Patrick and I were just on our world trip recently, and it's always really engaging and energizing for the two of us to be with all of our teams around the world. Yeah. Okay. And then maybe on margins, a good portion of the lab portfolio has been refreshed, I believe, at this point. And I think the idea for you is to replace products with those that have better margins. So is that something that you think can be meaningful when it comes to overall profitability next year? I think, I mean, no individual product launch moves the needle for us, but we have had a very good cadence recently. It definitely helps. I think you see it in our margin expansion this year. But I just kind of view that as part of the overall one of the ingredients of many that drives our overall margin expansion. But yeah, definitely something we're mindful of for sure. And I think even more importantly, the new products are very well received in the marketplace, and that drives our value proposition and ultimately a customer's willingness to pay. So it certainly helps us with our pricing in the market as well too. Okay. Thanks very much. The next question comes from Dan Leonard with UBS. Your line is open. Thanks for the time. I have a question about a potential change in the tariff environment. How are you preparing for any change, and is there anything different about your business today versus the 2018, 2019 timeframe when tariffs were a topic? Yeah. Good question. And yes, as you also point back to 2018, 2019, we definitely have really successfully navigated tariffs in the past as well. I mean, what has changed since then for us? Number one is we, of course, have also continued to really expand our production footprint worldwide and expand, for example, our Mexico production to supply the U.S. and providing us also with more manufacturing flexibility. So we have also started already over the last two years building some redundant manufacturing lines that we had initially only in China and now also in Mexico. But we have more flexibility as we have really global manufacturing footprint. China, Mexico, are not the only footprints we have. If there's more headwinds or changes out there, which we continuously monitor, we will, of course, tap into that opportunity to, as needed, then adjust our manufacturing footprint if that is needed. I think we have a unique advantage with our global supply chain, and we definitely continue to fully leverage that. I think we have definitely made the right steps to start early on de-risking the setup that we had with the bigger footprint in China and making sure we have enough redundancies. We will continue to do so, and I think it will actually, in that regard, I think we are still, of course, exposed to tariffs, but we are pretty, I think we are pretty good prepared to react on those. Appreciate that. And then a quick follow-up, Patrick. You mentioned that in speaking to your Process Analytics business, that destocking is fully behind you at this point. What does the growth rate of that business then look like in the absence of destocking? Is it back to traditional long-term growth rates, or is it something different? Yeah. Actually, we are extremely happy to see that the momentum in our Product Inspection business really has picked up. It's a clear sign that destocking is behind us. It's not only the size of the orders we receive, it's also the frequency of the orders we receive that really tells us that customers are back to normal operation. I think also with the launches of new products that we had over the last years, we are well positioned to maintain our strong market position there. And in terms of the growth rate, Shawn, do we have the growth rate for the last quarter for Product Inspection for ProView? It's basically within our Lab number and. Yeah. We don't give out specific numbers, but I would say within our lab portfolio, we had good growth throughout the portfolio, but we had very strong growth. I think it was double-digit in product Process Analytics. And by the way, we also had really good growth in analytical instruments. Okay. Thank you. The next question comes from Jack Meehan with Nephron Research. Your line is open. Thank you. Good morning. I wanted to ask a little bit about the assumptions on the fourth quarter guide. I was just doing some simple math. I think the revenue forecast implies something like 6% growth sequentially. I was just benchmarking, looking back. I think it was something more like a little over 10%. So I was just curious, if you look sequentially, why you were building in a little bit more conservatism than we've seen previously? I'm sorry, Jack, can you repeat it? I didn't pick it up. Yeah. Sequential. Just looking at the ramp from the third quarter to the fourth quarter on total sales, I think it's about 6% sequential growth is what your guide implies. In the past, it's been a little bit over 10%, just why you're embedding a little bit more conservatism. I'm sorry. Thanks. Yeah, yeah, yeah, yeah. So yeah, hey, I understand the question. Yeah, I think it might be even closer to 7% sequential, but I understand it. Yeah. Hey, we're a little bit more cautious right now. I think China is a big part of it on market conditions in general, but particularly China. I think if you kind of dig into the sequentials, you'll see China is the one that is more of the standout there, and yeah, and hey, I was a little distracted because I was just looking at the notes on this Process Analytics thing. We grew double-digit in Europe and in the U.S., but we grew high single digit globally. And then maybe just to follow up on, again, kind of this third quarter to fourth quarter dynamic, can you just remind us what you've historically seen as it pertains to a budget flush? I know some companies have more, it's a little bit more dynamic. But if you could just talk about what you're expecting in that regard and just what you're embedding in that. Yeah. And I think there's going to be. I think there's going to be some. We're not counting on a full flush. I mean, and I think you can see it with your first question, right? I think a typical five or 10-year average of sequentials from Q3 to Q4 is more in the 10% kind of a range. So you can tell we're not counting on a full flush. But I think part of that's also related to China. I mean, we hear mixed things when talking to our teams. I mean, there's definitely a lot of activity. We definitely see some positive things out there, but there's also things that are still delayed. And so it's a little bit on which customer you're talking to sometimes. Yeah. Sounds good. Thank you, Shawn. Yep. You're welcome. The next question comes from Rachel Vatnsdal with JPMorgan. Your line is open. Great. Good morning. Thanks for taking the questions. I wanted to follow up on some of the China comments, but really more focused on the near-term trends. So you mentioned that China returned to growth this quarter. You also highlighted that there's some excess capacity in some of the markets and pressures in industrial as well. So can you just unpack that for us a little bit more? And then, Shawn, you just mentioned on Jack's question that in terms of that 3Q to 4Q sequential ramp, some of that is pressured by China. So can you just walk us through what are your China assumptions into 4Q as well? Yeah. Sure. Maybe I'll start, and I'll let Patrick kind of pick it up, so a couple of positives. One, overall, we did return to growth. I mean, we've been going through a period in China now of very significant decreases. There's been kind of this resetting, if you will, over the last four quarters, so it was nice to see modest growth in the quarter. We did have low single-digit growth in the lab business, and then we had a low single-digit decline on the industrial business. In fairness to the industrial business, the lab had an easier comparison. I mean, our lab business kind of started to downturn a lot more than on the industrial side, and you could argue the industrials then held up pretty resiliently in spite of a very challenging market situation overall. So low single-digit relative to market conditions, I think, shows how well the team still continues to execute there. And Patrick and I were just there recently, and the industrial team was sharing with us a lot of the innovations that they've come out with also on the Laboratory side. And it's just really kind of neat to see the breadth of the things that they're doing locally and bringing to the market. In terms of how we're thinking about China for the fourth quarter, because of some of these comps, we're going to start seeing a little bit more divergence in terms of lab and industrial. We mentioned that the comp overall, well, I don't know. Did we give guidance for Q4? I I can't remember. So just to be clear, our guidance for Q4 for China is mid-single-digit growth. And if you exclude the impact of this shipping delay benefit, it's going to be more like low single-digit growth in the fourth quarter. And on a reported basis, that will kind of translate into more like low double-digit growth on the Laboratory side, acknowledging their lapping, still an easy comparison there. And then on the industrial side, we're expecting it to be down high single digit, maybe on the higher end of high single digit, might even round to a 10. We'll see how it plays out. Yeah. Excellent. Thanks, Shawn. If I may add, in terms of the question regarding unpacking the growth areas in China, I think we are seeing better recoveries in pharma and in Process Analytics, also in some of the special chemical spaces in China. That's recovering well. Again, also there, we have destocking behind us. The area where we still are not yet in the same recovery mode is in industrial automation. Part of that is also linked to areas that have seen exceptional growth over the last two years, like, for example, the battery segment in China, and truly, that's a capacity issue. I mean, they are sitting on a lot of overcapacity, so they are not, at the moment, investing in additional capacity expansion and automation solutions, and that's pulling some of our growth rates in China down on industrial automation. Great. That's all helpful. And then just as my follow-up, could you walk us through those 4Q assumptions by segment and geography in terms of what you're assuming, including the comp? Perfect. Thanks, guys. Yeah. Absolutely. I'm going to start with the top with lab. So like I did before for 2025, I'll give you the reported number, and then I'll give you the adjusted number for the shipping delay from last year. So on a reported basis, we expect lab to be up low double-digit, and on an adjusted basis for the shipping delay, up mid-single digit. The Core Industrial business, we expect to be up low single digit on a reported basis and down slightly low single digit on an adjusted basis for the shipping delay. For Product Inspection, we expect both to be up high single digit. So that would translate into a total industrial growth of mid-single digit on a reported basis and up low single digit on an adjusted basis. And then retail would be down about 10% on a reported basis and down high teens on an adjusted basis. And then as we look at the geographies, we estimate Americas will be up low to mid-single digit on a reported basis and flattish on an adjusted basis. Europe would be up low double-digit on a reported basis and up low single digit on an adjusted basis. And then China, we already mentioned, would be up mid-single digit on a reported basis and then up low single digit on an adjusted basis for the shipping delay. The next question comes from Josh Waldman with Cleveland Research. Your line is open. Hey, morning. Thanks for taking my questions. Patrick, it seems like you've made more of a point to talk on share gains over the last couple of quarters. Do you think you're seeing improvement in momentum here? And if so, is it more a function of a change in the competitive landscape or maybe the environment from, say, a customer preference or anything like that? Or is it more just building momentum on some of the internal service and sales efforts? Yeah. I think it's a bit of both, Josh. Thanks for the question. I mean, what we're seeing is that the products that we have launched in the different categories compete extremely well. And of course, we're also looking at growth numbers of our competitors in the last couple of quarters and see that we are doing really well. Despite the low growth environment, we are still outgrowing these competitors in many areas. We see also that our win-loss ratios in the markets that we serve are very stable, that our products are being well received by our customers, that our sales teams are really able to compete with this portfolio very effectively. And that's also part of the feedback Shawn and I got when we did our budget tour and talked to the market organizations worldwide. Actually, they are very happy with the products, the latest releases that we have in the different categories, whether it's lab, whether it's, for example, also Product Inspection. They can compete effectively with these new products that we have launched. And in some areas, we even went into market segments that we didn't serve before. If you think about the Product Inspection business, where we have launched a number of mid-range products, we call them. So at a more mid-range product level, we historically have been always the market leader and still are the market leader in high-end segment. But with this new portfolio, we can really also tap deeper into the mid-range product portfolio. And that's going very nicely for us. We have launched several X-ray products, and that is helping us winning in the mid-range, but also opening more doors and helping us to upsell some of this product portfolio. Again, it's a blend together with the strong go-to-market strategies that we have. Whenever we see new market segments, new hot segments, using our Top K Spinnaker portfolio to identify these customers, to prepare the right materials for our sales team, and get them in touch with these accounts and qualify the accounts and bring our portfolio top of mind of these new customers. I think that's a differentiation. That's really the combination of a strong, innovative product portfolio with the right sales tools to also get in front of the customers, also new customers that we don't serve today, is the winning recipe also moving forward. Got it. And then, Patrick, can you talk a bit more on the trend you're seeing within the pharma end market? I think you commented on strength in the U.S. and Europe. Is that more a benefit to Process Analytics and pipettes, or are you seeing improvement in instruments? And then based on what you're seeing from these accounts kind of real-time and where you expect to end the year, do you think we're on a path back to kind of normalized longer-term growth in 2025 from these accounts? Yeah. Good question. I mean, I talked a bit about Process Analytics in the pharma space and also the biopharma space. That is definitely back to good growth for us. And again, both in terms of order frequency and order volumes, we're very happy with that. On the analytical instrument side across the pharma business, I would also say we're seeing better sales engagement, better momentum, and for some accounts, still prolonged sales cycles, to be honest. I mean, there are customers out there who want to upgrade their portfolio, who see the benefit of new products, but it still takes them longer to get them through the internal approval cycles. But I'm quite optimistic that also that will, in the, let's say, quarters to come, we'll get back to more normal levels. Look, I mean, 70%-80% of our business is replacement business, and that had been tuned down for almost two years now. That also means moving forward, there is, at one point in time, when the budget will be released, there is a catch-up that we can capture, and that's why we are also really focusing so much on innovation and having the best updated portfolio out there to capture this wave when these budgets are released. Got it. Okay. Thank you. The next question comes from Patrick Donnelly with Citi. Your line is open. Hey, guys. Thank you for taking the questions. Shawn, I wanted to drill a little more into the margins. Certainly, get the moving pieces on 2025. It sounds like flat for 2025, mainly due to kind of the logistics catch-up. But I guess when you look at 2024, that was boosted by the logistics catch-up. I mean, would 2024 have been down on margins without that logistics catch-up? Again, just trying to kind of feel out the margin algorithm here, just given if we look at over a two, three-year period, just haven't seen much expansion. I guess one of the key levers going forward off of this are the China headwinds maybe weighing on things a little bit? Can you talk about the China margins? Just trying to dive into the margin piece, excluding some of that logistics if you can. Thank you. Yeah. Sure. I understand the question, Patrick. I mean, so if you look at 2024, our operating profit margin is expected to expand in the 50 basis points kind of range. You're right. If you exclude the shipping delay, that probably would have been down a little bit. It's kind of the same as you kind of look at the sales growth, right? The sales would have been I mean, we need to acknowledge volumes are still down. So if you adjust for the shipping delay. So what's our guidance? 2%. And if you exclude the 3%, we're - 1%. And then if you exclude pricing, volume's down 3%. So there's a reality there. But I think if you kind of look back, if you're just looking at the last couple of years, I think you're looking at a period where there hasn't been volume growth. But that's after a period where there was exceptional volume growth. And so I think you need to go back. If you really want to do a look back, I'd go back to 2019, pre-COVID, and our margins have expanded. At that time, they were under 26%. So we've had tremendous margin expansion still over this time. It just wasn't quite a straight line. Now, as we kind of look forward, we still remain very confident, as I mentioned earlier in the Q&A, in why do we remain confident? All the things that we have at our disposal to increase margins are still have a lot of runway to them. It starts with growing the business. We have a lot of opportunities there. We still serve very highly fragmented markets. We've been investing a lot on innovation. We just launched a new generation of Spinnaker 6. So we have plenty of opportunities to expand sales going forward. And then we talked about service today. Second is pricing. Pricing has been and will continue to be a key lever. We have a lot of very innovative things within the program. We have very sophisticated analytics. We have very sophisticated tools. We have teams all around the world working together with our market organizations and as well as our product organizations to optimize price. We have some pretty sophisticated things also in terms of our ability to provide pricing recommendations. And all this has been also supported well by our R&D pipeline, which is continuing to increase the value propositions of our products. And then Stern Drive, we talked about it earlier this year about launching the latest generation and wave of Stern Drive, which is about how do we improve efficiencies in the organization, primarily targeting our supply chain as well as reducing costs. Lots of very interesting things in that program. Still have many innings to go in terms of the runway there. Also, a lot of new technologies that we're able to take advantage of in our manufacturing setup to be more productive. And then on the last call, we talked about Blue Ocean. And that was also a little intentional to remind people of the power of Blue Ocean. And there's a lot of things that Blue Ocean gives us in terms of a foundation and an enabler for a lot of the programs we do, but it also helps us drive productivity, whether it's through the ability to automate processes and leverage shared service centers, but also providing better insights to make better decisions in the business through more advanced analytics. That's really helpful. Anything on the China margins quickly, if you don't mind? I think China is above corporate average margins, so it's been a bit of a headwind to our overall margin over the last year. But it's nice to see that we're starting to turn the corner there on growth and going forward, but nothing particular. Within China, we've addressed productivity issues there with the volume decrease. The team's been very focused on acknowledging that, but we also feel like we have a very strong organization that executes well and is prepared for the future, and I'd say our Chinese team is certainly one of the leaders in our company when it comes to areas like Stern Drive and driving productivity. And they're a very innovative organization. That's really helpful. Thanks, Shawn. And then, Patrick, just quickly on the industrial side, it sounds like China obviously weighing on things. Can you just talk industrial broadly? Is it mainly China that's the issue? And kind of what you're seeing on that front from customers would be helpful. Thank you, guys. Yeah. Yeah. Good question. Look, I mean, China is definitely a factor, as I said, but it's also in the U.S. and Europe that we have seen a slower market in the last quarter. Some of the areas, I would say it wouldn't take a pause, but also their decision cycle is taking a bit longer. If you compare, if you also look at the earnings reports of some of our competitors in the industrial space, you can see that some of the automation growth has been slowing down quite a bit. I think we're still competing very effectively, but we are not totally immune to these changes out there. I mean, PMI is, well, I don't want to always link it to PMIs, but it has been down for many quarters, and with that, there has been a subdued, I would say, investment in some of the industrial automation. I'm sure that will come back a bit because there is a need for productivity gains. There is also a shrinking workforce, if you look into Europe and the U.S., and that will require also investment in automation and digitalization, and our solutions are front and center here. They are empowering our customers to drive the needed productivity gains and also compliance when it comes to data handling, etc., so midterm, I'm not concerned about that, to be honest, again, we have a strong product portfolio. I think the trend for automation and digitalization will stay intact, but yes, we had a slower quarter this last quarter, and it was not only China. China was probably more prominent, but also the U.S. and Europe were somewhat smaller. Yeah. And as a reminder too, our industrial business, while it has more exposure to the general economy than our other businesses, about 60% of it still is anchored in our core segments of a combination of pharma, biopharma, food manufacturing, and chemical. But we also see a lot of these delays and things taking a little bit longer in our core segments as well too. It's not just the general economy. Very helpful. Thank you, guys. The next question comes from Tycho Peterson with Jefferies. Your line is open. Hey, thanks. Actually, just want to follow up on some of the industrial stuff. So Product Inspection, you're guiding to high single digit in the fourth quarter. I assume that's easy comp because you're talking about low single digit next year. But can you maybe just touch on food manufacturing? That's been a challenging business for a while. And any risks, I guess, with the new administration on deregulation for either that or broader parts of the portfolio? I know it's early days. Yeah. You want to? Yeah. I can start, and you can chime in, Shawn. Look, I mean, as I said in the beginning, the good news here is we are competing really well with Product Inspection with our upgraded portfolio with the new mid-range products. Yes, the market is still slow. Customers are under pressure. If you look at the big packaged food customers out there, they all, of course, are also under pressure when it comes to their margins. That's why what we're seeing is good engagement, but prolonged sales cycles. Still, Q4, I think, is a bit of an easier comp compared to last year. That's right. But midterm, I think we will stay in that low to mid-single digit range that we have forecasted for next year for PI. There's not a fundamental change I would expect from the current administration when it comes to the impact of packaged food companies, which is a large part of our customer base. Yeah. I mean, I think we need to see what they come out with. But I think what we find is every time there's a concern about, "Are people still going to buy whatever?" There's new brands. There's new sizes. There's new shapes. And so people are still going to eat. And so there tends to be always opportunities, even if there's risks with change. Yeah. There's, again, there's different modalities we serve from checkweighing, making sure that it's the right amount. And customers are as concerned that they package enough into the packaged food, but also not too much. So they want to have checkweighing at the end of the line. And then the other control when it comes to physical contamination, it's a brand protection for these companies. We make food safe, and our customers use it definitely as a big part of their brand protection. Nobody wants to find physical contamination in packaged food. Exactly. And And then, Patrick, I'm trying to reconcile your comments in the opening about just more onshoring, but then automation was soft in the Americas. I mean, when do you think automation actually turns here? Do you think you could actually overshoot next year, given some of the onshoring initiatives? We'd love to overshoot, of course, but I can tell you, I mean, that onshoring and reshoring process is something that we monitor very closely, but I mean, this takes also time, right? It's not like you shut down somewhere or you slow down your business in China and then move it within six months to the U.S. or to Europe. It takes time. I think you have not seen, I would say, the material part of the reshoring activities worldwide. That's still to come. When it really will gain momentum, probably more of that next year and the years to come, but the exact timing is difficult to forecast, to be honest. Okay. And the last one, Shawn, just pricing assumptions in the fourth quarter and then thinking about next year, obviously, with inflation coming down, what's your pricing power? Has the algorithm changed at all? No. Thanks, Tycho. We're still thinking 2% for Q4, and we're also thinking 2% for next year. Okay. Thank you. Thanks. And your final question comes from Michael Ryskin with Bank of America. Your line is open. Great. Thanks for sticking with me, guys. I'll be quick. First, Shawn, I want to confirm some comments you made earlier. I thought I heard you say that margins flat in 2025. I just want to make sure I heard that correctly. And it's not sort of an adjusted number, just a little bit hard to reconcile the EPS with guide with that. Is that kind of like flattish, maybe down a little bit, or is that a hard flat? So operating margins flattish. Yeah. Maybe. Yeah. And then the gross profit margin would be up like 30-40 basis points. Yeah. Okay. Yeah. All right. Exactly. That makes sense. And then sort of following up on that, on the shipping component, just want to make sure we back it out correctly, the way you kind of described it for 2024. Is it fair to say that ex-shipping margins would be up something like 50-75 basis points range, 50-70 basis points next year, and that's the swing? I'm just trying to do some math here. Yeah. I mean, I haven't, yeah, I don't know the exact math, but that sounds like a reasonable range to me. Okay. And then last one for me. I think Tycho was just asking about Product Inspection. I want to ask a little bit on Food Retail. I know it's not a critical part of your business. It's not something you talk about a lot, but that's just sort of been declining pretty consistently for a while. I mean, you often have tough comps, one-time customer issues, things like that. It's just gone from like 15% of revenues back in the day down to, I think, 5% and continues to face some challenges. Just taking a step back, what are your thoughts on that? I mean, is that something you continue to think can be a core part of the business, or could there be some strategic solutions there? Thanks. Good question. I mean, look, Food Retail, as you said, is a very lumpy business. We do a lot of key account management there. So a lot of the major customers and retail chains out there are buying from us, but they come in project waves. The decline you see this year is really on the back of a very strong year last year. Last year, we had a lot of good projects out there. Overall, it's still about 5% of our total revenues. We don't expect that to significantly increase. It's really a strong technology platform leverage that we have. It's a weighing solution. In that regard, we think it's still a valid part of our portfolio. We have invested actually a bit in the last couple of years updating the products. We came out with very new, really interesting solutions for customers, also using AI-based features to automatically detect what you put on the scale, simplifying the workflow not only for the customer, but also for the checkout service, and that's been received very well, so we see also, again, a good number of projects in the pipeline, but strategically, again, we don't think about any immediate change there other than having this part of a platform leverage and technology leverage of our portfolio. Okay. Makes sense. I'll leave it there. Thanks, guys. Thank you. This concludes the question and answer session. I'll turn the call to Adam for closing remarks. All right. Great. Hey, thanks, everybody, for joining us this morning. If you have any follow-up questions, please feel free to reach out. And I hope you all have a great weekend. Take care. This concludes today's conference call. Thank you for joining. You may now disconnect.